ArticlePloS one2012
Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Guideline
- Pooled it
- Salvage Liver Transplant versus Primary Liver Transplant for Patients with Hepatocellular Carcinoma.Annals of transplantation · 2018Pooled it
- 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.Gut and liver · 2015Guideline
- 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.Korean journal of radiologyGuideline
- Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges.World journal of gastrointestinal surgery · 2023Review
- Current status and prospect of treatments for recurrent hepatocellular carcinoma.World journal of hepatology · 2023Review
- Salvage versus Primary Liver Transplantation for Hepatocellular Carcinoma: A Twenty-Year Experience Meta-Analysis.Cancers · 2022Review
- Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature.Frontiers in oncology · 2022Review
- Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.Clinical journal of gastroenterology · 2021Review
- Salvage liver transplant for hepatocellular carcinoma: rescues and benefits.Translational gastroenterology and hepatology · 2018Review
- Salvage Liver Transplantation Leads to Poorer Outcome in Hepatocellular Carcinoma Compared with Primary Liver Transplantation.Scientific reports · 2017Article
- Limitations of predicting microvascular invasion in patients with hepatocellular cancer prior to liver transplantation.Scientific reports · 2017Article
- Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.World journal of hepatology · 2016Review
- Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria.Annals of surgery · 2016Article
- Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study.Oncotarget · 2016Article
- Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation.Translational gastroenterology and hepatology · 2016Review
- Surgical treatment of intra hepatic recurrence of hepatocellular carcinoma.World journal of hepatology · 2015Review
- Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma.World journal of hepatology · 2014Review
- The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.Journal of clinical and experimental hepatology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSalvage liver transplantation (SLT) is restricted to patients who develop hepatocellular carcinoma (HCC) recurrence within Milan criteria (MC). Little is known about outcomes for SLT in patients with recurrent HCC within University of California San Francisco (UCSF) criteria after liver resection (LR).
methodsBetween January 2001 and December 2011, 380 patients with HCC meeting UCSF criteria, 200 of which were resected (LR group) from a perspective of SLT in case of recurrence, and 180 directly underwent LT (PLT). We compared patient characteristics, perioperative and long-term outcomes between SLT and PLT groups. We also assessed the outcome of LR and PLT groups.
resultsAmong the 200 patients in LR group, 86 (43%) developed HCC recurrence and 15/86 (17%) of these patients presented HCC recurrence outside UCSF criteria. Only 39 of the 86 patients underwent SLT, a transplantation rate of 45% of patients with HCC recurrence. Compared with PLT group, LR group showed lower overall survival rate (P = 0.005) and higher recurrence rate (P = 0.006). Although intraoperative blood loss and required blood transfusion were more frequent in SLT group, the perioperative mortality and posttransplant complications were similar in SLT and PLT groups. The overall survival and recurrence rates did not significantly differ between the two groups. When stratifying by graft type in the SLT group, overall survival and recurrence rates did not significantly differ between deceased donor LT (DDLT) and living donor LT (LDLT) groups. In the subgroup analysis by MC, similar results were observed between patients with recurrent HCC meeting MC and patients with recurrent HCC beyond MC but within UCSF criteria.
conclusionOur single institution experience demonstrated that prior hepatectomy and SLT for recurrent HCC within UCSF criteria was feasible and SLT could achieve the same outcome as PLT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.